Fig. 1
From: Skp2 modulates proliferation, senescence and tumorigenesis of glioma
High expression level of Skp2 predicted poor prognosis in glioma. a Skp2 was overexpressed in various types of tumor tissues compared with paired normal tissues. b Skp2 mRNA levels were high in both LGG and GBM, but only significant in GBM. c In glioma (including both LGG and GBM), the OS was shorter for patients with high-level of Skp2 (n = 330) than those with low-level of Skp2(n = 331) (p < 0.0001). d In LGG, the OS was poorer in patients with high-level of Skp2 (n = 254) than those with a low-level of Skp2 (n = 256) (p < 0.0001). e There was no significant difference on OS between different mRNA levels of Skp2 in GBM. f The OS was analyzed according the IDH mutation status and Skp2 expression level (n = 507). g The OS was analyzed in LGG (n = 94) and GBM (n = 137) patients with IDHwt and different Skp2 levels. h The OS was analyzed by status of 1p19q co-deletion and Skp2 expression level in IDHmut LGG patients (n = 413) (BLCA: Bladder Urothelial Carcinoma; CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma; COAD: Colon adenocarcinoma; DLBC: Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; GBM: Glioblastoma; ESCA: Esophageal carcinoma; LUSC: Lung squamous cell carcinoma; READ: Rectum adenocarcinoma; STAD: Stomach adenocarcinoma; TGCT: Testicular Germ Cell Tumors; THYM: Thymoma; UCS: Uterine Carcinosarcoma)